Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Ketoconazole on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer
Sponsor: Celgene
Listed as NCT01324310, this PHASE1 trial focuses on Hematologic Malignancy and Malignant Lymphoma and remains completed. Sponsored by Celgene, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .